Antioxidant Therapy: Is it your Gateway to Improved Cardiovascular Health?

Mark SellkePharmaceutica 2014 · DOI

Abstract

General use and popularity of over-the-counter supplemental antioxidants have rapidly spread all over the world and are believed to promote cardiovascular health and wellbeing. However, there is a paucity of information and lack of proof that physiological and above-physiological levels of oxidants do harm at the cellular and organismal levels. Instead, several reports demonstrated that reduction in Reactive Oxygen Species (ROS) did not improve vascular function. Interestingly, recent studies show that increased ROS levels play protective role in vascular endothelium and may improve coronary endothelial function. In the current review, we introduce the concept that increased ROS levels, often seen in association with cardiovascular disease, probably is an endothelial-way or 'oxidative response' to cope with vascular pathology.

The Redox Paradox: Why Antioxidants Failed

For decades, the "oxidative stress" theory has dominated cardiovascular research. The logic was straightforward: cardiovascular diseases are consistently associated with high levels of Reactive Oxygen Species (ROS). These species were thought to quench nitric oxide (NO), leading to endothelial dysfunction, stiff blood vessels, and eventually, clinical events like atherosclerosis and diabetic complications.

Traditional model of oxidative stress where high ROS levels impair nitric oxide (NO) bioavailability, contributing to atherosclerosis and diabetic complications.

Based on this model, supplemental antioxidants like Vitamin E and Beta-Carotene were expected to be a panacea. However, large-scale clinical trials, such as the HOPE and ATBC studies, failed to show any reduction in cardiovascular mortality. This discrepancy between theory and clinical reality is known as the "Redox Paradox." It suggests that our understanding of ROS as a purely toxic byproduct is incomplete.

Challenging the Dogma: ROS as a Signaling Molecule

The failure of antioxidant trials suggests that association does not equal causation. High ROS levels in diseased hearts might not be the primary cause of damage, but rather a compensatory response. The role of ROS is highly dependent on its source (e.g., NADPH oxidase vs. mitochondria), its subcellular location, and its intensity.

Using a novel binary Tet-ON/OFF transgenic mouse model, researchers were able to specifically increase endogenous ROS within endothelial cells by upregulating NADPH oxidase 2 (Nox2). This allowed for the study of "physiological" increases in ROS—roughly a 1.8-fold increase—rather than the blunt, massive oxidative stress caused by chemical agents.

The "Oxidative Response" Model

Instead of "oxidative stress," the authors propose the concept of "oxidative compensation" or "oxidative response." In this model, moderate increases in ROS act as vital signaling molecules that activate protective cellular pathways.

The proposed 'oxidative response' pathway: moderate NOX2-derived ROS signals through AMPK to trigger protective autophagy and vasodilation.

A key mediator in this process is AMP-activated protein kinase (AMPK). When ROS levels increase moderately, they trigger the ROS-AMPK pathway, which mimics the beneficial effects of caloric restriction. This pathway activates several protective mechanisms:

  • Autophagy: A cellular "recycling" process that clears out damaged organelles, helping the cell survive stressful conditions.
  • Vasodilation: ROS can actually stimulate eNOS (endothelial nitric oxide synthase) activity, leading to increased NO production and improved blood flow.
  • Endothelial Proliferation: Promoting the health and density of the capillary network to improve vascular function.

Clinical Implications and Future Directions

If ROS is a necessary signal for maintaining vascular health, then high-dose, non-specific antioxidants might inadvertently block the body's natural repair mechanisms. This explains why blunt antioxidant therapy has failed: it may be "turning off" the very signals the heart uses to cope with pathology.

The line between a beneficial "oxidative response" and harmful "oxidative stress" remains thin. Future research must define the "tipping point" where ROS transitions from a helpful signal to a damaging toxin. Furthermore, we need better diagnostic tools to determine whether a patient is experiencing true oxidative damage or a necessary compensatory response before initiating therapy.

Conclusion

The shift from a reductionist "ROS is bad" view to a nuanced "oxidative response" model represents a significant step forward in cardiovascular medicine. By understanding the specific signaling roles of ROS, we can move toward more targeted therapies that support the body's natural defenses rather than blindly suppressing them.

Summary updated

Abstract

General use and popularity of over-the-counter supplemental antioxidants have rapidly spread all over the world and are believed to promote cardiovascular health and wellbeing. However, there is a paucity of information and lack of proof that physiological and above-physiological levels of oxidants do harm at the cellular and organismal levels. Instead, several reports demonstrated that reduction in Reactive Oxygen Species (ROS) did not improve vascular function. Interestingly, recent studies show that increased ROS levels play protective role in vascular endothelium and may improve coronary endothelial function. In the current review, we introduce the concept that increased ROS levels, often seen in association with cardiovascular disease, probably is an endothelial-way or 'oxidative response' to cope with vascular pathology.
BibTeX
@inproceedings{sellke2014antioxidant,
  author = {Mark Sellke},
  title = {{Antioxidant Therapy: Is it your Gateway to Improved Cardiovascular Health?}},
  booktitle = {Pharmaceutica},
  year = {2014},
  doi = {10.4172/2153-2435.1000323},
}
Figure